Hong Kong · Delayed Price · Currency is HKD PegBio Company Description
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China.
Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.
The company’s PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity.
It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia.
Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity.
It has research and development collaboration with rani therapeutics to expand obesity pipeline across multiple novel candidates.
PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
| Country | China |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Min Xu |
Contact Details
Address: Room 606 Hangzhou China | |
| Phone | 86 512 6295 6128 |
| Website | pegbio.com |
Stock Details
| Ticker Symbol | 2565 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100006T44 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Min Xu | Executive Chairman of the Board and GM |
| Xiaojun Wang | Chief Financial Officer and Executive Director |
| Chuanzhen Liu | Head of Regulatory Affairs |
| Jianhui Wang | Head of Macromolecular Drug Discovery |
| Dr. Nengyin Liu | Head of Drug Discovery |
| Yifeng HUANG | Joint Company Secretary and Board Secretary |
| Yan Ting Kwok | Joint Company Secretary |